These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25019570)

  • 1. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study.
    Hsu KF; Chou HH; Huang CY; Fu HC; Chiang AJ; Tsai HW; Chen JR; Cheng WF; Ke YM; Chang CC; Chen TH; Lin SH; Ho CM
    Gynecol Oncol; 2014 Sep; 134(3):516-22. PubMed ID: 25019570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
    Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
    Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review.
    Thomas M; Mariani A; Wright JD; Madarek EO; Powell MA; Mutch DG; Podratz KC; Dowdy SC
    Gynecol Oncol; 2008 Feb; 108(2):293-7. PubMed ID: 18096208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study.
    Sarı ME; Meydanlı MM; Türkmen O; Cömert GK; Turan AT; Karalök A; Şahin H; Haberal A; Kocaman E; Akbayır Ö; Erdem B; Numanoğlu C; Güngördük K; Sancı M; Gökçü M; Özgül N; Salman MC; Boyraz G; Yüce K; Güngör T; Taşkın S; Altın D; Ortaç UF; Ayık HA; Şimşek T; Arvas M; Ayhan A
    J Gynecol Oncol; 2017 Jul; 28(4):e49. PubMed ID: 28541637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
    Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
    Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy of uterine clear cell carcinoma: a review.
    Xu Y; Hanna RK; Elshaikh MA
    Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine Clear Cell Carcinoma: Does Adjuvant Chemotherapy Improve Outcomes?
    Nguyen JM; Bouchard-Fortier G; Bernardini MQ; Atenafu EG; Han G; Vicus D; Ferguson SE; Gien LT
    Int J Gynecol Cancer; 2017 Jan; 27(1):69-76. PubMed ID: 27668398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
    Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
    J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
    Armbruster SD; Previs R; Soliman PT; Westin SN; Fellman B; Jhingran A; Fleming ND
    Gynecol Oncol; 2019 Aug; 154(2):328-332. PubMed ID: 31221496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
    Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
    Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
    Ayeni TA; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; Haddock MG; Keeney GL; Long HJ; Dowdy SC; Podratz KC
    Gynecol Oncol; 2013 Jun; 129(3):478-85. PubMed ID: 23535279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
    Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
    Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
    Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
    Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis.
    Gockley AA; Rauh-Hain JA; Anders AM; Meyer LA; Clemmer J; Lu KH; Clark RM; Schorge JO; del Carmen MG
    Int J Gynecol Cancer; 2016 May; 26(4):697-704. PubMed ID: 26825834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of lymphadenectomy in uterine clear cell carcinoma.
    Mahdi H; Lockhart D; Moselmi-Kebria M
    J Gynecol Oncol; 2015 Apr; 26(2):134-40. PubMed ID: 25686398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hysterectomy for uterine adenocarcinoma in the elderly: tumor characteristics, and long-term outcome.
    Gayar OH; Robbins JR; Parikh K; Lu M; Buekers T; Munkarah A; Elshaikh MA
    Gynecol Oncol; 2011 Oct; 123(1):71-5. PubMed ID: 21767871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
    Bristow RE; Asrari F; Trimble EL; Montz FJ
    Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.